1. Home
  2. UNP vs NVO Comparison

UNP vs NVO Comparison

Compare UNP & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Union Pacific Corporation

UNP

Union Pacific Corporation

HOLD

Current Price

$258.74

Market Cap

157.1B

Sector

Industrials

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$47.41

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UNP
NVO
Founded
1862
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Railroads
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
157.1B
197.4B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
UNP
NVO
Price
$258.74
$47.41
Analyst Decision
Buy
Hold
Analyst Count
23
11
Target Price
$275.55
$51.00
AVG Volume (30 Days)
2.9M
11.4M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.08%
3.19%
EPS Growth
8.03
N/A
EPS
2.87
N/A
Revenue
$19,533,000,000.00
N/A
Revenue This Year
$5.57
N/A
Revenue Next Year
$4.29
$3.70
P/E Ratio
$90.56
$13.60
Revenue Growth
N/A
N/A
52 Week Low
$214.32
$35.12
52 Week High
$279.70
$71.80

Technical Indicators

Market Signals
Indicator
UNP
NVO
Relative Strength Index (RSI) 43.34 64.78
Support Level $217.43 $45.62
Resistance Level $272.75 $47.79
Average True Range (ATR) 6.45 1.41
MACD -1.47 0.28
Stochastic Oscillator 18.88 99.14

Price Performance

Historical Comparison
UNP
NVO

About UNP Union Pacific Corporation

Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24.5 billion of revenue in 2025 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: